Search

Your search keyword '"Sahin, Handan Haydaroğlu"' showing total 10 results
Start Over Author "Sahin, Handan Haydaroğlu"
10 results on '"Sahin, Handan Haydaroğlu"'

1. Incidence and risk factors for hepatic sinusoidal obstruction syndrome after allogeneic hematopoietic stem cell transplantation: A retrospective multicenter study of Turkish hematology research and education group (ThREG)

Author

Soyer, Nur, Gunduz, Mehmet, Tekgunduz, Emre, Deveci, Burak, Ozdogu, Hakan, Sahin, Handan Haydaroglu, Turak, Esra Ermis, Okay, Mufide, Kuku, Irfan, Hindilerden, Ipek Yonal, Topcuoglu, Pervin, Altuntas, Fevzi, Karadogan, Ihsan, Pehlivan, Mustafa, Unal, Ali, Goker, Hakan, Erkurt, Mehmet Ali, Besısık, Sevgi Kalayoglu, and Vural, Filiz

Published
2020
Full Text
View/download PDF

2. An Interim Analysis of the Turkish Myeloma Registry Among the Patients Who Have Received up to Two Lines of Therapy

Author

Sevindik, Omur Gokmen, Ozkurt, Zubeyde Nur, Boga, Can, Besisik, Sevgi Kalayoglu, Ipek, Yildiz, Geduk, Ayfer, Harmandali, Aybuke, Salihoglu, Ayse, Sahin, Handan haydaroglu, Sönmez, Mehmet, Vural, Filiz, Akay, Olga Meltem, Kurt Yuksel, Meltem, Maral, Senem, Ekinci, Omer, Kirkizlar, Onur Hakki, Tekinalp, Atakan, Demir, Nazli, Merter, Mustafa, Saydam, Guray, Alacacıoğlu, İnci, Yegin, Zeynep Arzu, Kasar, Mutlu, Mastanzade, Metban, and Ozsan, Guner Hayri

Published
2021
Full Text
View/download PDF

3. P-125: An interim analysis of the Turkish Myeloma Registry among patients who have received up to two lines of therapy

Author

Sevindik, Omur Gokmen, Özkurt, Zübeyde Nur, Boğa, Can, Besisik, Sevgi Kalayoglu, Ipek, Yıldız, Gedük, Ayfer, Harmandalı, Aybüke, Salihoğlu, Ayşe, Şahin, Handan Haydaroğlu, Sönmez, Mehmet, Vural, Filiz, Akay, Olga Meltem, Yüksel, Meltem Kurt, Maral, Senem, Ekinci, Ömer, Kırkızlar, Hakkı Onur, Tekinalp, Atakan, Demir, Nazlı, Merter, Mustafa, Saydam, Güray, Alacacioğlu, inci, Yeğin, Zeynep Arzu, Kasar, Mutlu, Mastanzade, Metban, and Özsan, Güner Hayri

Published
2021
Full Text
View/download PDF

6. Real-World Data in Relapsed Refractory Myeloma Patients Treated with Carfilzomib, a Multicenter Turkish Experience

Author

Sevindik, Omur Gokmen, Pehlivan, Mustafa, Tuglular, Tulin F, Solmaz, Serife M, Dogu, Mehmet Hilmi, Yalniz, Fevzi, Ural, Ali Ugur, Yeğen, Zafer Serenli, Arat, Mutlu, Ozkocaman, Vildan, Umit, Elif G, Şahin, Handan Haydaroğlu, Sönmez, Mehmet, Turgut, Mehmet, Ozcan, Muhit, Arslan, Onder, Aydin, Yildiz, Elibol, Tayfun, Harmandali Olgun, Aybuke, Bayar, Banu, Tombak, Anil, Aydogdu, Ismet, and Özsan, Güner Hayri

Published
2017
Full Text
View/download PDF

9. Q192R and L55M Polymorphisms of Paraoxonase 1 Gene in Chronic Myelogenous Leukemia and Chronic Lymphocytic Leukemia.

Author

Tomatir AG, Pehlivan S, Sahin HH, Balci SO, Budeyri S, and Pehlivan M

Subjects
Adolescent, Adult, Aged, Case-Control Studies, Female, Humans, Male, Middle Aged, Young Adult, Aryldialkylphosphatase genetics, Genetic Predisposition to Disease, Leukemia, Lymphocytic, Chronic, B-Cell genetics, Leukemia, Myelogenous, Chronic, BCR-ABL Positive genetics, Polymorphism, Single Nucleotide genetics
Abstract

Aim: The aim of the present study was to investigate the association between Paraoxonase 1 (PON1) gene polymorphisms Q192R, and L55M in patients with Chronic Myelogenous Leukemia (CML) and Chronic Lymphocytic Leukemia (CLL) patients., Materials and Methods: We analyzed samples from 60 patients with CML, 60 with CLL and 84 healthy controls. Polymerase Chain Reaction (PCR)--Restriction Fragment Length Polymorphism (RLFP) was performed and samples were run in agarose gel., Results: We found statistically significant results showing an increase in both the RR genotype (p=0.044) and the R allele (p=0.011) for PON1 Q192R, and an increase in the MM genotype (p=0.007) and a decrease in the LL genotype (p=0.004) and R allele (p=0.001) in PON1 L55M in patients with CLL., Conclusion: We concluded that both the Q192R gene polymorphism with an increase in the genotype R allele, and the M/L55 with an increase in the MM genotype play a role in CLL susceptibility, and a decrease in the LL genotype can act against disease in the Turkish population., (Copyright© 2015 International Institute of Anticancer Research (Dr. John G. Delinassios), All rights reserved.)

Published
2015

10. Two cases with hypereosinophilic syndrome shown with real-time PCR and responding well to imatinib treatment.

Author

Selvi N, Kaymaz BT, Sahin HH, Pehlivan M, Aktan C, Dalmızrak A, Inalpolat E, Kosova B, Yılmaz M, Okan V, and Saydam G

Subjects
Humans, Hypereosinophilic Syndrome drug therapy, Hypereosinophilic Syndrome genetics, Imatinib Mesylate, Male, Middle Aged, Molecular Diagnostic Techniques, Oncogene Proteins, Fusion genetics, Polymorphism, Restriction Fragment Length, Real-Time Polymerase Chain Reaction, Receptor, Platelet-Derived Growth Factor alpha genetics, Treatment Outcome, mRNA Cleavage and Polyadenylation Factors genetics, Benzamides therapeutic use, Hypereosinophilic Syndrome diagnosis, Piperazines therapeutic use, Pyrimidines therapeutic use
Abstract

The aim of this work was to report two cases of hypereosinophilic syndrome (HES). FIP1L1-PDGFRA fusion was assessed with two protocols at RNA level. The fusion transcript was found positive at the RNA level with both PCR methods in two cases. In this study, the efficiency of imatinib treatment and a dramatic response in two HES cases with multisystemic involvement showing the characteristics of a chronic myeloproliferative disease were presented. Both cases showed complete responses confirming that imatinib mesylate treatment could be successful even in patients with advanced HES having myeloproliferative disease.

Published
2013
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results